Select Medical Dividend Overview and Recent Influential News Before Ex-Dividend Date on Aug 13, 2025
Generated by AI AgentAinvest Dividend Digest
Saturday, Aug 9, 2025 7:13 pm ET1min read
SEM--
Aime Summary
Select Medical Holdings Corporation (NYSE: SEM) has announced a dividend of $0.063 per share, with an ex-dividend date set for Aug 13, 2025. This dividend amount is notably lower compared to the average of the last ten dividends, which stood at approximately $0.165 per share. The dividend announcement was made on Jul 30, 2025, and the payout is scheduled for Aug 28, 2025. The previous dividend, paid on May 29, 2025, was also $0.063 per share. The dividends are categorized as cash dividends.
Recently, Select MedicalSEM-- Holdings has experienced noteworthy developments that could impact its market performance and financial health. As of late, MizuhoMFG-- lowered its price target for Select Medical from $21.00 to $18.00, while maintaining an Outperform rating. This adjustment reflects analysts’ perspectives on the company's future profitability amidst evolving market conditions.
Over the past week, Select Medical reported mixed results for its Q2 2025 earnings, revealing that its revenue had grown by nearly 5% to $1.3 billion. Despite this revenue growth, the company's shares saw a decline of 20% following the earnings announcement on Jul 31, 2025. This drop indicates investor apprehension regarding the company's broader financial outlook.
Since the last update, Select Medical's stock has been influenced by strategic decisions and investments, including a new investment by XTX Topco Ltd. The stock opened at $11.89 on a recent Friday, with a market capitalization of $1.47 billion. Although the stock experienced a minor decrease of 0.5%, the investment highlights ongoing interest and potential for growth in the company.
In conclusion, Select Medical Holdings is navigating a complex financial landscape. The upcoming ex-dividend date on Aug 13, 2025, marks the last opportunity for investors to acquire shares to receive this dividend, with any purchase made post-ex-dividend date not qualifying for the current payout.
Recently, Select MedicalSEM-- Holdings has experienced noteworthy developments that could impact its market performance and financial health. As of late, MizuhoMFG-- lowered its price target for Select Medical from $21.00 to $18.00, while maintaining an Outperform rating. This adjustment reflects analysts’ perspectives on the company's future profitability amidst evolving market conditions.
Over the past week, Select Medical reported mixed results for its Q2 2025 earnings, revealing that its revenue had grown by nearly 5% to $1.3 billion. Despite this revenue growth, the company's shares saw a decline of 20% following the earnings announcement on Jul 31, 2025. This drop indicates investor apprehension regarding the company's broader financial outlook.
Since the last update, Select Medical's stock has been influenced by strategic decisions and investments, including a new investment by XTX Topco Ltd. The stock opened at $11.89 on a recent Friday, with a market capitalization of $1.47 billion. Although the stock experienced a minor decrease of 0.5%, the investment highlights ongoing interest and potential for growth in the company.
In conclusion, Select Medical Holdings is navigating a complex financial landscape. The upcoming ex-dividend date on Aug 13, 2025, marks the last opportunity for investors to acquire shares to receive this dividend, with any purchase made post-ex-dividend date not qualifying for the current payout.
Sip from the stream of US stock dividends. Your income play.
Latest Articles
Stay ahead of the market.
Get curated U.S. market news, insights and key dates delivered to your inbox.
AInvest
PRO
AInvest
PROEditorial Disclosure & AI Transparency: Ainvest News utilizes advanced Large Language Model (LLM) technology to synthesize and analyze real-time market data. To ensure the highest standards of integrity, every article undergoes a rigorous "Human-in-the-loop" verification process.
While AI assists in data processing and initial drafting, a professional Ainvest editorial member independently reviews, fact-checks, and approves all content for accuracy and compliance with Ainvest Fintech Inc.’s editorial standards. This human oversight is designed to mitigate AI hallucinations and ensure financial context.
Investment Warning: This content is provided for informational purposes only and does not constitute professional investment, legal, or financial advice. Markets involve inherent risks. Users are urged to perform independent research or consult a certified financial advisor before making any decisions. Ainvest Fintech Inc. disclaims all liability for actions taken based on this information. Found an error?Report an Issue

Comments
No comments yet